Zeggwagh A A, Abouqal R, Madani N, Abidi K, Moussaoui R, Zekraoui A, Kerkeb O
Service de réanimation médicale et de toxicologie clinique, hôpital Avicenne, Rabat, Maroc.
Ann Fr Anesth Reanim. 2002 Nov;21(9):703-9. doi: 10.1016/s0750-7658(02)00779-7.
To compare nebulized salbutamol and nebulized adrenaline in acute severe asthma (ASA).
Prospective controlled study.
October 1998 at May 99, 44 patients (31 women and 13 men, 35 +/- 11 yrs) with ASA (defined as peak expiratory flow rate (PEF) < 150 l min-1 and normo- or hypercapnia) were randomized to receive either nebulized salbutamol (n = 22), 10 mg/h-1 during 2 h then 5 mg every 4 h or nebulized adrenaline (n = 22), 6 mg/h-1 during 2 h then 3 mg every 4 h. The efficacy was assessed by PEF, forced expiratory volume in one second (FEV1) and Fischl's score during eight hours and by arterial blood gases during the first hour. Side-effects were evaluated by heart rate, systolic blood pressure, serum potassium and blood glucose. Statistical tests: Wilcoxon, Fischer exact, ANOVA and Scheffe's test.
Both groups were similar with respect to age, sex, severity, duration of asthma and length of crisis. With the two treatments, PEF increased significantly but no statistical difference were observed between the two groups during the eight hours: 117.7 +/- 41.6 l min-1 to 203.3 +/- 56.9 l min-1 in the salbutamol group; 116.4 +/- 36.8 l min-1 to 217.3 +/- 188.8 l min-1 in the adrenaline group; p = 0.77. FEV1, Fischl's score and arterial blood gases did not differ significantly between treatments at every time interval. There were no significant difference between the two groups in terms of side-effects. The intravenous way was necessary at 3 cases of the salbutamol group and 4 cases of adrenaline group (NS).
The results suggest that nebulized adrenaline is as effective as nebulized salbutamol in the ASA without significant side-effects. The nebulization could reduce systemic effects of adrenaline.
比较雾化沙丁胺醇和雾化肾上腺素治疗急性重度哮喘(ASA)的效果。
前瞻性对照研究。
1998年10月至1999年5月,44例ASA患者(31例女性,13例男性,35±11岁,定义为呼气峰值流速(PEF)<150升/分钟且伴有正常或高碳酸血症)被随机分为两组,分别接受雾化沙丁胺醇(n = 22)治疗,2小时内以10毫克/小时的速度给药,之后每4小时给予5毫克;或雾化肾上腺素(n = 22)治疗,2小时内以6毫克/小时的速度给药,之后每4小时给予3毫克。在8小时内通过PEF、一秒用力呼气量(FEV1)和菲施尔评分评估疗效,在第1小时通过动脉血气评估疗效。通过心率、收缩压、血清钾和血糖评估副作用。统计检验:威尔科克森检验、费舍尔精确检验、方差分析和谢费检验。
两组在年龄、性别、病情严重程度、哮喘病程和发作持续时间方面相似。两种治疗方法均可使PEF显著增加,但在8小时内两组之间未观察到统计学差异:沙丁胺醇组从117.7±41.6升/分钟增加到203.3±56.9升/分钟;肾上腺素组从116.4±36.8升/分钟增加到217.3±188.8升/分钟;p = 0.77。在每个时间间隔,两种治疗方法的FEV1、菲施尔评分和动脉血气均无显著差异。两组在副作用方面无显著差异。沙丁胺醇组有3例、肾上腺素组有4例需要采用静脉给药方式(无统计学差异)。
结果表明,雾化肾上腺素在治疗ASA方面与雾化沙丁胺醇效果相同,且无明显副作用。雾化可减少肾上腺素的全身效应。